scispace - formally typeset
R

Ronald G. Tompkins

Researcher at Harvard University

Publications -  531
Citations -  44641

Ronald G. Tompkins is an academic researcher from Harvard University. The author has contributed to research in topics: Burn injury & Poison control. The author has an hindex of 93, co-authored 526 publications receiving 41859 citations. Previous affiliations of Ronald G. Tompkins include University of Toronto & Tulane University.

Papers
More filters
Journal ArticleDOI

Long-term functional recovery of hepatocytes after cryopreservation in a three-dimensional culture configuration.

TL;DR: The sandwich culture configuration enables hepatocytes to maintain a satisfactory level of long-term protein secretion after a freeze-thaw cycle under optimized conditions, and offers an attractive tool for further studies into the mechanisms of freezing injury and subsequent hepatocellular recovery.
Journal ArticleDOI

Cellular Distribution of Endotoxin after Injection of Chemically Purified Lipopolysaccharide Differs from That after Injection of Live Bacteria

TL;DR: Comparison of injections of live Escherichia coli O111:B4 bacteria with LPS extracted from the same strain showed that cellular localization and time course in rat organs were markedly different after the two injections of LPS.
Journal ArticleDOI

Antibody-targeted photolysis: in vitro studies with Sn(IV) chlorin e6 covalently bound to monoclonal antibodies using a modified dextran carrier.

TL;DR: A monoclonal antibody-dextran-Sn(IV) chlorin e6 immunoconjugate was prepared by a technique involving the site-specific covalent modification of the monoclotal antibody oligosaccharide moiety, which showed excellent retention of antigen binding activity relative to the unmodified antibody.
Journal ArticleDOI

Are topical antimicrobials effective against bacteria that are highly resistant to systemic antibiotics

TL;DR: MDRs are more resistant to topicals than are non-MDROs, and some treatment assumptions based historically on the efficacy of topical antimicrobial agents against non- MDROs need to be re-evaluated.